Sheila E. Taube

Active 1965–2018

14
Papers
18,924
Citations
14
h-index
14
i10-index

Citations

Citations per year for Sheila E. Taube1966: 1 citations1967: 2 citations1968: 2 citations1969: 1 citations1970: 1 citations1971: 2 citations1972: 1 citations1978: 1 citations1992: 1 citations1998: 5 citations1999: 1 citations2000: 3 citations2001: 7 citations2002: 8 citations2003: 8 citations2004: 8 citations2005: 18 citations2006: 25 citations2007: 51 citations2008: 122 citations2009: 156 citations2010: 201 citations2011: 264 citations2012: 261 citations2013: 234 citations2014: 276 citations2015: 253 citations2016: 195 citations2017: 180 citations2018: 152 citations2019: 576 citations2020: 575 citations2021: 434 citations2022: 240 citations2023: 146 citations2024: 240 citations2025: 93 citations2026: 6 citations1973–1977: no citations, so these years are not shown1979–1991: no citations, so these years are not shown1993–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,623 citing papers, 22.2% of this breakdownUnited Kingdom: 610 citing papers, 8.4% of this breakdownChina: 579 citing papers, 7.9% of this breakdownGermany: 398 citing papers, 5.4% of this breakdownItaly: 338 citing papers, 4.6% of this breakdownCanada: 320 citing papers, 4.4% of this breakdownFrance: 274 citing papers, 3.8% of this breakdownNetherlands: 260 citing papers, 3.6% of this breakdownSpain: 235 citing papers, 3.2% of this breakdownSouth Korea: 218 citing papers, 3% of this breakdownJapan: 207 citing papers, 2.8% of this breakdownSwitzerland: 182 citing papers, 2.5% of this breakdown
0%22.2%Other 28.2%

Fields

  • Medicine50.8%
  • Biochemistry, Genetics and Molecular Biology40.2%
  • Computer Science2.7%
  • Immunology and Microbiology2.2%
  • Chemistry0.8%
  • Decision Sciences0.6%
  • Other2.7%

Topics

  • Breast Cancer Treatment Studies10%
  • HER2/EGFR in Cancer Research7.1%
  • Cancer Genomics and Diagnostics3.5%
  • Cancer Cells and Metastasis3.2%
  • Cancer Immunotherapy and Biomarkers3.2%
  • Breast Lesions and Carcinomas3.1%
  • Other69.9%

Coauthors

All papers

Open in search
  1. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James L. Wittliff, Antonio C. Wolff - Archives of Pathology & Laboratory Medicine 2010 cited by 4,267

  2. REporting recommendations for tumour MARKer prognostic studies (REMARK)

    Authors: , , , , , - British Journal of Cancer 2005 cited by 1,387

  3. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration

    Authors: , , , , - JNCI Journal of the National Cancer Institute 2018 cited by 495

  4. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Archives of Pathology & Laboratory Medicine 2006 cited by 4,475

  5. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James L. Wittliff, Antonio C. Wolff - Archives of Pathology & Laboratory Medicine 2010 cited by 1,048

  6. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

    Authors: , , , - BMC Medicine 2012 cited by 1,032

  7. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

    Authors: , , , , , , , , - Journal of Clinical Oncology 2007 cited by 2,216

  8. Reporting recommendations for tumor marker prognostic studies (remark).

    Authors: , , , , , - Breast Cancer Research and Treatment 2005 cited by 2,085

  9. A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment

    Authors: , , , , , - JNCI Journal of the National Cancer Institute 2009 cited by 127

  10. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers

    Authors: , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 1996 cited by 752

  11. Reporting Recommendations for Tumor Marker Prognostic Studies

    Authors: , , , , , - Journal of Clinical Oncology 2005 cited by 775

  12. Breaking a Vicious Cycle

    Authors: , , , , , , , , , , , , - Science Translational Medicine 2013 cited by 121

  13. Influence of inhibitors of protein synthesis on interferon formation in mice

    Authors: , , - Virology 1965 cited by 107

  14. A system for sharing routine surgical pathology specimens across institutions: the Shared Pathology Informatics Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Human Pathology 2007 cited by 37

All 14 papers shown.